168 related articles for article (PubMed ID: 31558234)
1. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV
J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234
[No Abstract] [Full Text] [Related]
2. Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.
Huang Y; Gan J; Guo K; Deng Y; Fang W
J Thorac Oncol; 2019 Oct; 14(10):e236-e237. PubMed ID: 31558239
[No Abstract] [Full Text] [Related]
3. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
Xie Z; Gu Y; Xie X; Lin X; Ouyang M; Qin Y; Zhang J; Lizaso A; Chen S; Zhou C
Clin Lung Cancer; 2021 May; 22(3):e390-e394. PubMed ID: 32693944
[No Abstract] [Full Text] [Related]
4. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
5. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
6. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
7. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract][Full Text] [Related]
8. EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.
Batra U; Sharma M; Amrith BP; Mehta A; Jain P
Clin Lung Cancer; 2020 Nov; 21(6):e597-e600. PubMed ID: 32620470
[No Abstract] [Full Text] [Related]
9. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S; Lin X; Sun S; Li S; Zhou C
Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
[TBL] [Abstract][Full Text] [Related]
10. Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF
Zhou F; Zhao W; Chen X; Zhang J; Zhou C
Lung Cancer; 2020 Jan; 139():219-220. PubMed ID: 31640894
[No Abstract] [Full Text] [Related]
11. Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF
Chic N; Mezquita L; Aldea M; Chebib R; Caramella C; Planchard D; Besse B
Clin Lung Cancer; 2021 Jan; 22(1):e54-e56. PubMed ID: 32896487
[No Abstract] [Full Text] [Related]
12. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
[No Abstract] [Full Text] [Related]
13. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
14. A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
Fang W; Huang Y; Gan J; Hong S; Zhang L
J Thorac Oncol; 2019 Sep; 14(9):e201-e202. PubMed ID: 31445736
[No Abstract] [Full Text] [Related]
15. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Zheng S; Li H; Feng J; Jiang C; Lin Y; Xie Y; Yu T; Qian X; Yin Z
Anticancer Drugs; 2022 Jan; 33(1):e795-e798. PubMed ID: 34486539
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
17. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y; Jiang G; Ma W; Li T; Wang L
Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
[No Abstract] [Full Text] [Related]
18. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
[TBL] [Abstract][Full Text] [Related]
19. Divergent
Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
[No Abstract] [Full Text] [Related]
20. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
[Next] [New Search]